DrugPatentWatch Database Preview
Daiichi Sankyo Inc Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for DAIICHI SANKYO INC, and when can generic versions of DAIICHI SANKYO INC drugs launch?
DAIICHI SANKYO INC has five approved drugs.
There are fourteen US patents protecting DAIICHI SANKYO INC drugs.
There are two hundred and sixty-seven patent family members on DAIICHI SANKYO INC drugs in forty-three countries and eighteen supplementary protection certificates in fourteen countries.
Summary for Daiichi Sankyo Inc
| International Patents: | 267 |
| US Patents: | 14 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
| Patent Litigation for Daiichi Sankyo Inc: | See patent lawsuits for Daiichi Sankyo Inc |
Drugs and US Patents for Daiichi Sankyo Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | RX | Yes | Yes | 10,189,833 | Start Trial | Start Trial | ||||
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-001 | Jan 8, 2015 | RX | Yes | No | 9,149,532 | Start Trial | Y | Start Trial | |||
| Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-004 | Oct 2, 2015 | RX | Yes | Yes | 7,955,619 | Start Trial | Y | Start Trial | |||
| Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-002 | Oct 2, 2015 | RX | Yes | No | 7,955,619 | Start Trial | Y | Start Trial | |||
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-002 | Jan 8, 2015 | RX | Yes | No | Start Trial | Start Trial | |||||
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-003 | Jan 8, 2015 | RX | Yes | Yes | 9,149,532 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Daiichi Sankyo Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | EVOXAC | cevimeline hydrochloride | CAPSULE;ORAL | 020989-002 | Jan 11, 2000 | 5,580,880 | Start Trial |
| Daiichi Sankyo Inc | EVOXAC | cevimeline hydrochloride | CAPSULE;ORAL | 020989-002 | Jan 11, 2000 | 4,855,290 | Start Trial |
| Daiichi Sankyo Inc | EVOXAC | cevimeline hydrochloride | CAPSULE;ORAL | 020989-002 | Jan 11, 2000 | 5,340,821 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for DAIICHI SANKYO INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 30 mg | ➤ Subscribe | 2009-02-27 |
| ➤ Subscribe | Tablets | 15 mg, 30 mg and 60 mg | ➤ Subscribe | 2019-01-28 |
| ➤ Subscribe | Powder for Oral Suspension | 1.875 g/Packet and 3.75 g/Packet | ➤ Subscribe | 2010-04-09 |
| ➤ Subscribe | Tablets | 15 mg, 30 mg, 60 mg and 100 mg | ➤ Subscribe | 2019-01-28 |
| ➤ Subscribe | Tablets | 625 mg | ➤ Subscribe | 2009-07-01 |
International Patents for Daiichi Sankyo Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Colombia | 2017011534 | Start Trial |
| Australia | 2013235298 | Start Trial |
| Canada | 2444028 | Start Trial |
| Netherlands | 300760 | Start Trial |
| Australia | 2002346300 | Start Trial |
| Mexico | PA03009568 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Daiichi Sankyo Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1405852 | 122015000077 | Germany | Start Trial | PRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
| 2140867 | 292 50001-2018 | Slovakia | Start Trial | PRODUCT NAME: EDOXABAN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/15/993 20150623 |
| 1405852 | C01405852/01 | Switzerland | Start Trial | PRODUCT NAME: EDOXABAN; REGISTRATION NO/DATE: SWISSMEDIC 65149 31.03.2015 |
| 1405852 | CA 2015 00052 | Denmark | Start Trial | PRODUCT NAME: EDOXABAN, HERUNDER EDOXABAN TOSILATE; REG. NO/DATE: EU/1/15/993/001-028 20150623 |
| 1405852 | 2015/045 | Ireland | Start Trial | PRODUCT NAME: EDOXABAN, A SALT THEREOF, A SOLVATIC THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
| 0764174 | SPC/GB04/031 | United Kingdom | Start Trial | PRODUCT NAME: COLESEVELAM HYDROCHLORIDE; REGISTERED: UK EU/1/03/268/001-003 20040310 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
